Key Points
- Roivant CEO Matthew Gline sold 1,740,000 shares on Dec. 15 at an average price of $21.68 for total proceeds of $37,723,200, cutting his ownership by 9.14% to 17,290,820 shares (worth about $374.9M).
- ROIV stock opened at $22.70 and is trading near its 52‑week high ($23.47) with a $15.79B market cap; analysts have a consensus "Moderate Buy" and a $24.81 average price target.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Matthew Gline sold 1,740,000 shares of the firm's stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $21.68, for a total value of $37,723,200.00. Following the transaction, the chief executive officer owned 17,290,820 shares of the company's stock, valued at $374,864,977.60. This trade represents a 9.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Matthew Gline also recently made the following trade(s):
- On Thursday, September 18th, Matthew Gline bought 3,315 shares of Roivant Sciences stock. The shares were purchased at an average cost of $15.07 per share, with a total value of $49,957.05.
Roivant Sciences Stock Performance
Shares of NASDAQ ROIV opened at $22.70 on Thursday. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $23.47. The company's 50 day moving average price is $19.76 and its 200-day moving average price is $14.95. The company has a market capitalization of $15.79 billion, a P/E ratio of -40.54 and a beta of 1.22.
Institutional Trading of Roivant Sciences
Hedge funds and other institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp grew its holdings in shares of Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company's stock valued at $25,000 after buying an additional 1,148 shares during the last quarter. Allworth Financial LP boosted its stake in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after purchasing an additional 583 shares during the last quarter. Bessemer Group Inc. increased its holdings in Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock worth $28,000 after purchasing an additional 543 shares in the last quarter. CWM LLC raised its stake in shares of Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company's stock worth $34,000 after purchasing an additional 920 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Roivant Sciences by 94.8% in the first quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company's stock valued at $46,000 after purchasing an additional 2,233 shares in the last quarter. Institutional investors own 64.76% of the company's stock.
Wall Street Analysts Forecast Growth
ROIV has been the topic of several research analyst reports. Wall Street Zen upgraded Roivant Sciences from a "strong sell" rating to a "hold" rating in a research report on Sunday, November 16th. Leerink Partners increased their price target on Roivant Sciences from $29.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday. Citigroup boosted their target price on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, November 11th. Guggenheim reissued a "buy" rating on shares of Roivant Sciences in a research note on Thursday. Finally, Weiss Ratings raised shares of Roivant Sciences from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Saturday, October 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $24.81.
Read Our Latest Stock Analysis on Roivant Sciences
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
